Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Matsuda, Morihiro ^a   Tamura, Ritsu ^a   Kanno, Kotaro ^a   Segawa, Takatsugu ^a   Kinoshita, Haruyuki ^a   Nishimoto, Orie ^a   Nishiyama, Hirohiko ^a   Kawamoto, Toshiharu ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Adiponectin; Coronary artery disease; Diabetes mellitus; HDL cholesterol; MDA LDL; Metabolic syndrome; Statins; Triglycerides

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METFORMIN; PHENYLALANINE DERIVATIVE; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN TISSUE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84889017457     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-77     Document Type: Article

References (50)

1. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Group. NDR, Circ J 2006 70 1249 1255 10.1253/circj.70.1249 16998254 (Pubitemid 44453215)
2. Optimal medical therapy with or without PCI for stable coronary disease. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, et al. N Engl J Med 2007 356 1503 1516 10.1056/NEJMoa070829 17387127 (Pubitemid 46588415)
3. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Lancet 2005 366 1267 1278 16214597
4. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, et al. Circulation 2006 113 2363 2372 10.1161/CIRCULATIONAHA.106.174516 16702489 (Pubitemid 43947981)
5. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL, N Engl J Med 1989 320 915 924 10.1056/NEJM198904063201407 2648148 (Pubitemid 19101597)
6. Oxidized LDL and HDL: antagonists in atherothrombosis. Mertens A, Holvoet P, FASEB J 2001 15 2073 2084 10.1096/fj.01-0273rev 11641234 (Pubitemid 32927925)
7. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D, Circulation 1998 98 1487 1494 10.1161/01.CIR.98.15.1487 9769301 (Pubitemid 28481664)
8. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R, Arterioscler Thromb Vasc Biol 2000 20 2243 2247 10.1161/01.ATV.20.10.2243 11031210
9. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, et al. Circulation 2001 103 1955 1960 10.1161/01.CIR.103.15.1955 11306523 (Pubitemid 32322222)
10. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F, Arterioscler Thromb Vasc Biol 2001 21 844 848 10.1161/01.ATV.21.5.844 11348884 (Pubitemid 32448777)
11. Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Shigematsu S, Takahashi N, Hara M, Yoshimatsu H, Saikawa T, Circ J 2007 71 1697 1702 10.1253/circj.71.1697 17965487 (Pubitemid 350240088)
12. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Tamura A, Watanabe T, Nasu M, Circ J 2003 67 816 820 10.1253/circj.67.816 14578611 (Pubitemid 37229216)
13. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L, Diabetes Care 2001 24 683 689 10.2337/diacare.24.4.683 11315831 (Pubitemid 32893993)
14. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB, Diabetes 2004 53 1068 1073 10.2337/diabetes.53.4.1068 15047623 (Pubitemid 38436620)
15. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr, JAMA 2008 299 2287 2293 10.1001/jama.299.19.2287 18492970 (Pubitemid 351724395)
16. Elevated circulating oxidized LDL levels in Japanese subjects with the metabolic syndrome. Yamagishi S, Matsuoka H, Kitano S, Hibi N, Jinnouchi Y, Umei H, Iida S, Takenaka K, Matsui T, Nakamura K, Imaizumi T, Int J Cardiol 2007 118 270 272 10.1016/j.ijcard.2006.06.058 17030446 (Pubitemid 46601658)
17. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, et al. Nat Med 2002 8 731 737 10.1038/nm724 12068289 (Pubitemid 34778727)
18. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, et al. J Biol Chem 2002 277 37487 37491 10.1074/jbc.M206083200 12138120
19. Plasma adiponectin levels and risk of myocardial infarction in men. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB, JAMA 2004 291 1730 1737 10.1001/jama.291.14.1730 15082700 (Pubitemid 38489895)
20. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Lindberg S, Pedersen SH, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Jensen JS, Am J Cardiol 2012 109 492 496 10.1016/j.amjcard.2011.09.041 22105783
21. Predictive value of adiponectin in patients with multivessel coronary atherosclerosis detected on computed tomography angiography. Matsuda M, Tamura R, Kishida N, Segawa T, Kanno K, Nishimoto O, Nakamoto K, Nishiyama H, Kawamoto T, J Atheroscler Thromb 2013 20 767 776 10.5551/jat.18036 23759798
22. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al. Biochem Biophys Res Commun 1999 257 79 83 10.1006/bbrc.1999.0255 10092513 (Pubitemid 29299050)
23. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Qiao L, Zou C, van der Westhuyzen DR, Shao J, Diabetes 2008 57 1824 1833 10.2337/db07-0435 18375436
24. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Tsujii K, Ishigami M, et al. Biochem Biophys Res Commun 2007 358 1091 1095 10.1016/j.bbrc.2007.05. 040 17521614 (Pubitemid 46829000)
25. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Ohama T, Ishigami M, et al. FEBS Lett 2007 581 5029 5033 10.1016/j.febslet.2007.09.038 17936760 (Pubitemid 47576080)
26. Hypoadiponectinemia is an independent risk factor for hypertension. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, et al. Hypertension 2004 43 1318 1323 10.1161/01.HYP.0000129281.03801.4b 15123570 (Pubitemid 38691756)
27. Adiponectin as a biomarker of the metabolic syndrome. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T, Circ J 2004 68 975 981 10.1253/circj.68.975 15502375 (Pubitemid 39540124)
28. Increased oxidative stress in obesity and its impact on metabolic syndrome. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I, J Clin Invest 2004 114 1752 1761 15599400 (Pubitemid 40385531)
29. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Lautamaki R, Ronnemaa T, Huupponen R, Lehtimaki T, Iozzo P, Airaksinen KE, Knuuti J, Nuutila P, Metabolism 2007 56 881 886 10.1016/j.metabol.2007.01.018 17570246 (Pubitemid 46900837)
30. The committee of japan diabetes society on the diagnostic criteria of diabetes mellitus: report of the committee on the classification and diagnostic criteria of diabetes mellitus. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki A, Ito C, Inagaki N, Iwamoto Y, Kasuga M, et al. Diabetol Int 2010 1 2 20 10.1007/s13340-010-0006-7
31. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S, Yamamura T, Clin Chem 2007 53 2128 2135 10.1373/clinchem.2007.092296 17901111 (Pubitemid 350197296)
32. Metabolic syndrome. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, et al. J Atheroscler Thromb 2008 15 1 5 10.5551/jat.E580 18319538
33. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E, Circulation 2002 106 1211 1218 10.1161/01.CIR.0000027569.76671.A8 12208795 (Pubitemid 34988638)
34. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Anderson RA, Evans ML, Ellis GR, Graham J, Morris K, Jackson SK, Lewis MJ, Rees A, Frenneaux MP, Atherosclerosis 2001 154 475 483 10.1016/S0021-9150(00)00499-8 11166782 (Pubitemid 32146622)
35. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW, Circulation 2004 109 1022 1028 10.1161/01.CIR.0000117403.64398.53 14967724 (Pubitemid 38282856)
36. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M, J Clin Invest 1995 96 2882 2891 10.1172/JCI118359 8675659
37. C-reactive protein levels and outcomes after statin therapy. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, N Engl J Med 2005 352 20 28 10.1056/NEJMoa042378 15635109 (Pubitemid 40075677)
38. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the aggrastat-to-zocor trial. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E, Circulation 2006 114 281 288 10.1161/CIRCULATIONAHA.106.628909 16847150 (Pubitemid 44297094)
39. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL, Circulation 2007 115 1408 1416 10.1161/CIRCULATIONAHA.106.666941 17339545 (Pubitemid 46648376)
40. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Li R, Wang WQ, Zhang H, Yang X, Fan Q, Christopher TA, Lopez BL, Tao L, Goldstein BJ, Gao F, Ma XL, Am J Physiol Endocrinol Metab 2007 293 1703 E1708 10.1152/ajpendo.00462.2007 17895290 (Pubitemid 350255122)
41. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham study. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ, Arterioscler Thromb Vasc Biol 2003 23 434 439 10.1161/01.ATV.0000058402.34138.11 12615693 (Pubitemid 36337219)
42. Role of AMP-activated protein kinase in mechanism of metformin action. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. J Clin Invest 2001 108 1167 1174 11602624 (Pubitemid 32995375)
43. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Satoh N, Shimatsu A, Yamada K, Aizawa-Abe M, Suganami T, Kuzuya H, Ogawa Y, Metabolism 2006 55 786 793 10.1016/j.metabol.2006.01.016 16713439
44. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, et al. Diabetes 2001 50 2094 2099 10.2337/diabetes.50.9.2094 11522676 (Pubitemid 33643677)
45. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I, Diabetes 2003 52 1655 1663 10.2337/diabetes.52.7.1655 12829629 (Pubitemid 36792453)
46. Adipose expression of catalase is regulated via a novel remote PPARgamma-responsive region. Okuno Y, Matsuda M, Kobayashi H, Morita K, Suzuki E, Fukuhara A, Komuro R, Shimabukuro M, Shimomura I, Biochem Biophys Res Commun 2008 366 698 704 10.1016/j.bbrc.2007.12.001 18073138
47. Human catalase gene is regulated by peroxisome proliferator activated receptor-gamma through a response element distinct from that of mouse. Okuno Y, Matsuda M, Miyata Y, Fukuhara A, Komuro R, Shimabukuro M, Shimomura I, Endocr J 2010 57 303 309 10.1507/endocrj.K09E-113 20075562
48. Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Lee YS, Kim AY, Choi JW, Kim M, Yasue S, Son HJ, Masuzaki H, Park KS, Kim JB, Mol Endocrinol 2008 22 2176 2189 10.1210/me.2008-0023 18562625
49. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998 352 854 865 9742977
50. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, JAMA 2003 290 486 494 10.1001/jama.290.4.486 12876091 (Pubitemid 37430502)